Metsera's MET-233i Achieves Placebo-Subtracted Weight Loss Up To 8.4% at Day 36 With No Safety Signals

Benzinga · 06/09 11:04
  • Placebo-subtracted mean weight loss up to 8.4% at Day 36
  • 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination
  • Well-tolerated with no safety signals